Key Highlights
- Phio Pharmaceuticals secured multiple favorable patent actions, comprising three notices of allowance and one grant decision, across the US, Canada, and Japan.
- These additions strengthen the clinical-stage biotech's total issued patent portfolio to 54 patents covering its proprietary INTASYL self-delivering siRNA gene-silencing platform.
- The IP package comprehensively covers INTASYL's unique chemistry, specific gene targets, immuno-oncology compounds, and therapeutic indications.
- CEO Robert Bitterman said the patent advancements will serve as critical strategic assets to facilitate future biopharma partnerships and protect commercial pathways.
Phio Pharmaceuticals Corp. (NASDAQ: PHIO) announced it has secured multiple favorable patent actions, comprising three notices of allowance and one grant decision, expanding global intellectual property protection for its proprietary INTASYL self-delivering siRNA gene-silencing platform. These new patent actions were issued across key international markets including the United States, Canada, and Japan.
With these additions, Phio's total issued patent portfolio now stands at 54 patents, a substantial intellectual property estate for a clinical-stage biotech company of Phio's size. Building a robust patent portfolio is a critical strategic priority for companies developing novel therapeutic platforms, as it establishes legal barriers to competitive imitation while also serving as a valuable asset in potential licensing or partnership negotiations.
The robust IP package resulting from these actions comprehensively covers INTASYL's unique chemistry, specific gene targets, immuno-oncology compounds, and therapeutic indications. This breadth of coverage, spanning both the underlying platform chemistry and specific downstream applications, provides Phio with layered protection across multiple dimensions of its technology, rather than relying on a single narrow patent claim.
INTASYL represents Phio's proprietary approach to self-delivering siRNA (small interfering RNA) technology, a gene-silencing platform designed to enable localized delivery of RNA-based therapeutics without requiring the additional delivery vehicles or formulations that many other siRNA approaches depend upon. This self-delivering characteristic is a key differentiating feature of the platform that the newly expanded patent estate helps protect.
According to CEO Robert Bitterman, these patent advancements will serve as critical strategic assets to facilitate future biopharma partnerships, accelerate internal research and development, and protect the company's eventual commercial pathways for localized gene-silencing therapies. This framing underscores how intellectual property serves multiple strategic purposes beyond simple legal protection, functioning as a tool for attracting potential partners and investors who require confidence in a technology's defensibility before committing resources.
For a clinical-stage biotech company like Phio, a strengthening patent position across major international markets provides an important foundation as the company continues to advance INTASYL-based therapeutic candidates through development, potentially supporting future partnership discussions with larger biopharmaceutical companies interested in licensing access to the platform's gene-silencing capabilities.






Please wait processing your request...